References
- Currie CJ, Poole CD, Tetlow T, et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23\(Suppl. 1):S33–S39
- Poole CD, Tetlow T, McEwan P, et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23\(Suppl. 1):S41–S48
- Greenland S. Small-sample bias and corrections for conditional maximum-likelihood odds-ratio estimators. Biostatistics 2000;1:113–22
- Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol 2000;151:531–9
- Bero L, Oostvogel F, Bacchetti P, et al. Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than Others. PLoS Med 2007;4:e184
- Pieber TR, Treichel H-C, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007 [doi:10.1111/j.1464-5491.2007.02113.x]
- Miskin R. Medical review of insulin detemir. FDA Centre for Drug Evaluation and Research: Application – 21–536, June, 2005. Available at: www.fda.gov/cder/foi/nda/2005/021–536_Levemir_medr.pdf [Last accessed: 12 June 2007]